GlobeNewswire Inc | Jan 3, 2022 04:01PM EST

January 03, 2022

HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present atthe 40thAnnualJ.P. Morgan Healthcare ConferenceonMonday, January 10, 2022 at 1:30 p.m. Eastern Time.

A live webcast of Kiniksas presentation will be accessible through the Investors & Media section of the companys website atwww.kiniksa.com. A replay of the webcast will also be available on Kiniksas website within approximately 48 hours after the event.

About KiniksaKiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksas portfolio assets, ARCALYST(rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visitwww.kiniksa.com.

ARCALYSTis a registered trademark ofRegeneron Pharmaceuticals,Inc.

Every Second Counts!^

Kiniksa Investor and Media ContactRachel Frank(339) 970-9437rfrank@kiniksa.com